Marc serves as general partner at Nina Capital and holds board directorships at Zetta Genomics and Methinks AI. He previously operated as general manager of international business at Teladoc Health.
The funding extension was backed by new investor We Venture Capital alongside returning backers Nina Capital, Apex Ventures, and Cambridge Enterprise to prepare the firm for Series A.
"Zetta Genomics is already making a difference to patients as XetaBase empowers clinicians to make faster and more accurate diagnoses at scale. With this extension to our second seed funding round now finalised, we are scaling and innovating our technologies, and enhancing customer focus."
Nina Capital led the seed follow on round to support international growth and product scaling.
"Today’s seed funding exceeded our initial ask, showing the excitement building around Zetta Genomics’ game changing XetaBase data analytics platform. We now have the strategic headroom to configure for growth – to scale our technologies, enhance customer focus, and create a cycle of ongoing product innovation. This investment sees us one step closer to realising predictive, precision genomics – transforming research, healthcare and the lives of millions."
The seed round was co-led by Speedinvest and Nina Capital to fund international expansion and team growth.
"The time to invest in Women’s reproductive health is now. Alice’s ability to build community, content, and tools that women love but have never had access to is second- to-none. Contraception is just the start of The Lowdown’s bold vision in Women’s health and we are thrilled to be supporting them on it!"